Abstract Background: Allogenic hematopoietic stem cell transplantation is a treatment option for children with diagnoses that for some reason prevent an adequate hematopoiesis, immune function or enzyme production. The treatment is a potential cure for otherwise life-threatening diseases, but offers a risk for both acute and chronic complications. There are made great advances for HSCT from the start of its history and forward to this date. Material and methods: This is a retrospective analysis of transplantation data registered for all pediatric patients transplanted in Norway at the National Hospital Rikshospitalet, during the time period from 1974-2014. We summarize the number of transplants, patient characteristics, transplantation details and some observed changes over time. In addition, survival rates are presented. Results: From 1974-2014, 283 allo-HSCT on 267 children were performed, and annual numbers are rising. Median age was 5, 65 years, 26 % of the transplantations where preformed before the age of 2 years and there are more boys than girls. 57 % where transplanted for a malignant disease. Sibling donors and unrelated donors where used equally common overall 90 %, and there is a marked rise in the use of unrelated donors over time. Overall survival at 3 months, 1 year and 5 years is respectively 83 %, 70 % and 61 %. We were not able to find any changes in the overall survival over time for the whole patient group. However, survival rates seem to vary between the different diagnoses. Conclusion: In this retrospective analysis, advancements in treatment procedures have not improved survival in first year after treatment when all transplanted patients are analyzed as a group. Changes in survival rates of the subgroups of patients, and other endpoints like transplantrelated morbidity, relapse risk and late effects were not addressed in this analysis. Patients should be transplanted within study protocols and prospective trials, and it would be interesting to evaluate the cause of death, other acute complications and late complications and quality of life among survivors in further analyses.